nach oben

01.12.2018 | Non-Hodgkin-Lymphome | Case report | Ausgabe 1/2018 Open Access

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report

Zeitschrift:: BMC Cancer > Ausgabe 1/2018

Autoren:: Alessandro Broccoli, Laura Nanni, Vittorio Stefoni, Claudio Agostinelli, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani

» Zum Volltext PDF-Version jetzt herunterladen

Abstract

Background

No standard of care is established for plasmablastic lymphoma (PBL) and prognosis remains extremely poor, given that patients relapse early after chemotherapy and display resistance to commonly applied cytostatic drugs.

Case presentation

We report a case of nodal, HIV-unrelated PBL in a patient who achieved and maintained a very long lasting complete remission after an intensive therapy consisting consisting of thalidomide plus dexamethasone followed by a consolidation with double autologous stem cell transplantation. Our approach was based on the full application of a standard multiple myeloma treatment and, to the best of our knowledge, it represents the only reported experience so far. This treatment was overall well tolerated.

Conclusions

Multiple myeloma-like treatment may represent a possible alternative to intensive lymphoma-directed therapies.

Campo E, Stein H, Harris NL. Plasmablastic lymphoma In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al, Eds. IARC Press, Lyon, France, Revised 4th edition; 2017. p. 317, 321–322.

Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica. 2004;89:826–31. PubMed

Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–30. CrossRefPubMed

Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991–9. CrossRefPubMed

Valera A, Balagué O, Colomo L, Martínez A, Delabie J, Taddesse-Heath L, et al. Ig/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686–94. PubMedPubMedCentral

Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15:293–9. CrossRefPubMedPubMedCentral

Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic stem cell transplantation for plasmablastic lymphoma: a review. Biol Blood Marrow Transplant. 2014;20:1877–84. CrossRefPubMed

Saba NS, Dang D, Saba J, Cao C, Janbain M, Maalouf B, et al. Bortezomib in plasmablastic lymphoma: a case report and review of the literature. Onkologie. 2013;36:287–91. CrossRefPubMed

Yan M, dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77–80. CrossRefPubMed

10.

Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352–5. CrossRefPubMed

11.

Hirosawa M, Morimoto H, Shibuya R, Shimajiri S, Tsukada J. A striking response of plasmablastic lymphoma of the oral cavity to bortezomib: a case report. Biomark Res. 2015;3:28. CrossRefPubMedPubMedCentral

12.

Fedele PL, Gregory GP, Gilbertson M, Shortt J, Kumar B, Opat S, et al. Infusional dose-adjusted EPOCH plus bortezomib for the treatment of plasmablastic lymphoma. Ann Hematol. 2016;95:667–8. CrossRefPubMed

13.

Cencini E, Fabbri A, Guerrini S, Mazzei MA, Rossi V, Bocchia M. Long-term remission in a case of plasmablastic lymphoma treated with COMP (cyclophosphamide, liposomal doxorubicin, vincristine, prednisone) and bortezomib. Eur J Haematol. 2016;96:650–4. CrossRefPubMed

14.

Carras S, Regny C, Peoc’h M, Gervasoni J, Gressin R, Cahn JY, et al. Dramatic efficacy of low dose lenalidomide as single agent in a patient with refractory gastric non-human immunodeficiency virus-associated plasmablastic lymphoma. Leuk Lymphoma. 2015;56:2986–8. CrossRefPubMed

15.

Schmit JM, DeLaune J, Norkin M, Grosbach A. A case of plasmablastic lymphoma achieving complete response and durable remission after lenalidomide-based therapy. Oncol Rest Treat. 2017;40:46–8. CrossRef

Titel: A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report
Autoren:: Alessandro Broccoli
Laura Nanni
Vittorio Stefoni
Claudio Agostinelli
Lisa Argnani
Michele Cavo
Pier Luigi Zinzani
Publikationsdatum: 01.12.2018
Schlagwörter: Non-Hodgkin-Lymphome
Stammzell-Transplantation
Chemotherapie
Diagnostik in der Onkologie
DOI: https://doi.org/10.1186/s12885-018-4561-9
Verlag: BioMed Central
Zeitschrift: BMC Cancer
Ausgabe 1/2018
Elektronische ISSN: 1471-2407

Passend zum Thema

Innovativer Ansatz: personalisierte Therapie mit CAR-T-Zellen

Es gibt Tumoren, die Tumorantigene nur schwach exprimieren und so der Immunantwort entkommen können. Ein neuer Therapieansatz – die CAR-T-Zelltherapie – kann die eigenen Immunzellen des Patienten dazu befähigen, den Tumor wieder zu identifizieren. Lesen Sie, was Sie zur Therapie wissen sollten.

CAR-T-Zelltherapie: Ablauf der „lebenden Krebstherapie“

Maligne Tumoren entstehen, wenn das Immunsystem die Tumorzellen nicht ausreichend bekämpfen kann. Ein neuer Therapieansatz, die CAR-T-Zelltherapie, nutzt T-Zellen des Patienten und befähigt sie dazu, die Tumorzellen zu identifizieren und zu bekämpfen. Lesen Sie mehr zur „lebenden Krebstherapie“.

OH-Ton – Trifft den Ton in der Onkologie & Hämatologie

Maßgeschneiderte Krebstherapien für bessere Überlebensaussichten, Prädiktion des Therapieansprechens oder genaue Prognosen von Krankheitsverläufen in der Onkologie: Informieren Sie sich zur Therapie verschiedener Tumorentitäten und dem State of the Art auf dem Weg zu einer personalisierten Medizin.

Bildnachweise

Hematoxylin-eosin staining showing macrophages admixed to plasmoblasts conferring a "starry-sky" appearrance/© Broccoli et al., Individuelle Krebstherapie/© Bristol Myers Squibb, Innovativer Ansatz/© Bristol Myers Squibb, CH OH-Ton/© Bristol Myers Squibb

Springer Medizin

Abstract

Background

Case presentation

Conclusions

Weitere Artikel der Ausgabe 1/2018

Serum Se, Ni, and As are associated with HPV infection and CIN2+ among Uyghur women in rural China

Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population

A suppressive role of guanine nucleotide-binding protein subunit beta-4 inhibited by DNA methylation in the growth of anti-estrogen resistant breast cancer cells

The effect of surgery on the survival status of patients with locally advanced cervical cancer after radiotherapy/chemoradiotherapy: a meta-analysis

Feasibility of concomitant cisplatin with hypofractionated radiotherapy for locally advanced head and neck squamous cell carcinoma

Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized

Passend zum Thema

Innovativer Ansatz: personalisierte Therapie mit CAR-T-Zellen

CAR-T-Zelltherapie: Ablauf der „lebenden Krebstherapie“

OH-Ton – Trifft den Ton in der Onkologie & Hämatologie

Association of genetic polymorphisms CYP2A62 rs1801272 and CYP2A69 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population